For sales

Highlights from the Week of 07th September – 14th September in the world of pharma and healthcare!

Highlights from the Week of 07th September 2026 - 14th September 2026 ( FDA, Accelerated Approval ) FDA provides accelerated approval to Bayer's sevabertinib to treat locally advanced or metastatic NSCLC with HER2/ERBB2 tumors ( FDA, Priority Review ) FDA accepts Takeda's TAK-279 under Priority Review to treat adults with moderate-to-severe plaque psoriasis ( FDA, Priority Review ) Genentech receives Priority Review from FDA for its sBLA, ENSPRYNG to treat MOGAD ( FDA, Fast Track ) Sobi obtains Fast Track designation from FDA for pacritinib to treat VEXAS syndrome Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.